[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100555992":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":28,"centralContacts":33,"locations":39,"responsibleParty":55,"collaborators":59,"id":61,"slug":10,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":62,"sex":67,"minAge":68,"maxAge":10,"enrollmentInfo":69,"targetDuration":10,"studyType":72,"phases":10,"briefSummary":73,"conditions":74,"keywords":82,"overallStatus":42,"whyStopped":10,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"ICI group",null,"Patients that receive immune checkpoint inhibitors",[13,14],"Diagnostic Test: Coronary computed tomography angiography (CCTA) at baseline","Diagnostic Test: Coronary computed tomography angiography (CCTA) after 1 year",{"label":16,"type":10,"description":17,"interventionNames":18},"Non-ICI group","Patients with similar malignancies, who do not receive immune checkpoint inhibitors",[13,14],[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":10},"DIAGNOSTIC_TEST","Coronary computed tomography angiography (CCTA) at baseline","Detailed imaging of coronary arteries",[9,16],{"type":21,"name":26,"description":23,"armGroupLabels":27,"otherNames":10},"Coronary computed tomography angiography (CCTA) after 1 year",[9,16],[29],{"name":30,"affiliation":31,"role":32},"H.W.M. van Laarhoven, Prof. Dr.","secretariaat.oncologie@amsterdamumc.nl","PRINCIPAL_INVESTIGATOR",[34],{"name":35,"role":36,"phone":37,"phoneExt":10,"email":38},"A Strijdhorst","CONTACT","+31 205665975","a.strijdhorst@amsterdamumc.nl",[40],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Amsterdam UMC","RECRUITING","Amsterdam","North Holland","1105AZ","Netherlands",{"type":48,"coordinates":49},"Point",[50,51],4.88969,52.37403,{"lat":51,"lon":50},[54],{"name":35,"role":36,"phone":37,"phoneExt":10,"email":38},{"type":56,"investigatorFullName":57,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Hanneke W. M. van Laarhoven","Principal Investigator",[60],{"name":41,"class":6},"100555992",false,"NCT06519292","Immune Checkpoint Inhibitor Associated Cardiovascular Adverse Events in Patients With Cancer","ITHACA","Inclusion Criteria:\n\n* Patients with confirmed diagnosis of the following tumor types, any stage: esophageal, gastric or junction cancer, colorectal cancer, non-small cell lung carcinoma, melanoma, renal cell carcinoma\n* Prior to start of new therapy (i.e. immune checkpoint inhibitor, chemotherapy or follow-up in case of esophageal cancer)\n* Age ≥ 50 years\n\nExclusion Criteria:\n\n* ICI therapy in previous 12 months\n* Suspected or confirmed viral, fungal, or bacterial infectious disease\n* Use of immunosuppressive therapy prior to ICI start\n* Estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73m2\n* Known allergy to iodinated contrast agents\n* Atrial fibrillation","ALL","50 Years",{"count":70,"type":71},214,"ESTIMATED","OBSERVATIONAL","Immune checkpoint inhibitors (ICI) have revolutionized cancer treatment and are now approved for various types of cancer. The most common side effects of ICI are immune-related adverse events which can affect any organ or system in the body. Recently, concerns have also risen about cardiovascular effects of ICI. Retrospective studies showed an 4-5 times increased risk of developing an arterial thromboembolic event.\n\nThe mechanisms driving the ICI-associated risks of arterial thromboembolic events such as myocardial infarction and stroke, are unclear. Since the risk of a thromboembolism appears to be increased already during the first months after initiation of ICI, immune-related hypercoagulability or (autoimmune) antiphospholipid antibodies may play a role, but data to support this are lacking. The longer-term risk of arterial thromboembolism may be predominantly driven by (accelerated) atherosclerosis, a chronic low-grade inflammatory disease of the larger arteries. Therefore, this study evaluates the effect of ICI on progression of coronary non-calcifid plaque volume by using computed tomography angiography (CCTA).",[75,76,77,78,79,80,81],"Cardiovascular Diseases","Arterial Thrombosis","Myocardial Infarction","Stroke","Coronary Artery Disease","Atherosclerosis","Cancer",[83,84,85],"immune checkpoint inhibitors","cardiovascular disease","atherosclerosis","2025-05-20",{"date":88,"type":89},"2025-05-22","ACTUAL",{"date":91,"type":89},"2023-01-25",{"date":93,"type":71},"2025-12-31",{"name":57,"class":6},1]